Truist Financial Upgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to Strong-Buy

Ultragenyx Pharmaceutical (NASDAQ:RARE) was upgraded by analysts at Truist Financial to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other research firms have also recently weighed in on RARE. Robert W. Baird reduced their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research note on Tuesday, December 30th. Wells Fargo & Company reduced their price objective on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research report on Tuesday, December 30th. Bank of America decreased their price objective on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, January 2nd. Wedbush restated a “neutral” rating and set a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 17th. Finally, HC Wainwright cut their target price on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $60.47.

Ultragenyx Pharmaceutical Trading Up 0.8%

Shares of Ultragenyx Pharmaceutical stock opened at $20.00 on Wednesday. Ultragenyx Pharmaceutical has a 1 year low of $18.29 and a 1 year high of $42.37. The company’s fifty day simple moving average is $22.44 and its 200-day simple moving average is $28.18. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -3.42 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The company had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. During the same quarter in the previous year, the company earned ($1.39) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% compared to the same quarter last year. As a group, research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 54,404 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the sale, the chief executive officer directly owned 658,994 shares in the company, valued at approximately $15,025,063.20. This represents a 7.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Karah Herdman Parschauer sold 8,135 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $185,478.00. Following the completion of the transaction, the executive vice president directly owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. The trade was a 9.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 104,958 shares of company stock valued at $2,394,858. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several institutional investors have recently bought and sold shares of the stock. Assetmark Inc. raised its stake in Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares in the last quarter. Huntington National Bank raised its position in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares during the last quarter. Danske Bank A S bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at $39,000. Smartleaf Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,169 shares in the last quarter. Finally, Covestor Ltd grew its holdings in shares of Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Truist upgraded Ultragenyx to “strong‑buy,” a supportive catalyst that can attract buyers and provide near‑term technical support. Truist upgrade (Zacks)
• Negative Sentiment: Goldman Sachs downgraded RARE to “Neutral” (coverage widely reported), a move cited in press accounts that coincided with the stock hitting a 12‑month low in some outlets — weighing on investor sentiment and downward pressure from institutional analysts. Goldman Sachs downgrade
• Negative Sentiment: Multiple law firms and shareholder‑claim services have filed or publicized securities class‑action notices and are soliciting lead‑plaintiff applicants for alleged misstatements during the Aug. 3, 2023–Dec. 26, 2025 class period; the April 6, 2026 lead‑plaintiff deadline is being highlighted repeatedly — this increases legal uncertainty, potential settlement risk, and headline volatility. Representative notices: Rosen Law Firm / Newsfile and Pomerantz (PR Newswire). Rosen Law Firm notice Pomerantz notice

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.